Valerio Therapeutics completes acquisition of Etherna Immunotherapies

PUBT · 2d ago
Valerio Therapeutics completes acquisition of Etherna Immunotherapies
  • Valerio Therapeutics completed the acquisition of Etherna Immunotherapies, taking 100% of its share capital and voting rights.
  • Deal valued Etherna at an enterprise value of EUR 30 million, funded through cash consideration and share consideration.
  • Cash portion was funded via issuance of 68,220,333 new ordinary shares at EUR 0.59 each, raising about EUR 40.25 million.
  • Transaction expands an integrated RNA platform spanning nucleic acid chemistry, lipid nanoparticle delivery, targeted moiety engineering, manufacturing.
  • Post-transaction share capital totals 587,615,993 shares, with Artal International holding 42.6%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202610120219BIZWIRE_USPR_____20261011_BW213857) on October 12, 2026, and is solely responsible for the information contained therein.